{"entity": "publication", "iuid": "5e267b6affe340de890b1f3012debc73", "timestamp": "2026-08-29T04:16:43.748Z", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/5e267b6affe340de890b1f3012debc73.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/5e267b6affe340de890b1f3012debc73"}}, "title": "ORF6 and ORF61 Expressing MVA Vaccines Impair Early but Not Late Latency in Murine Gammaherpesvirus MHV-68 Infection.", "authors": [{"family": "Samreen", "given": "Baila", "initials": "B"}, {"family": "Tao", "given": "Sha", "initials": "S"}, {"family": "Tischer", "given": "Karsten", "initials": "K"}, {"family": "Adler", "given": "Heiko", "initials": "H"}, {"family": "Drexler", "given": "Ingo", "initials": "I"}], "type": "journal article", "published": "2019-12-18", "journal": {"title": "Front Immunol", "issn": "1664-3224", "volume": "10", "pages": "2984", "issn-l": "1664-3224"}, "abstract": "Gammaherpesviruses (\u03b3HV) are important pathogens causing persistent infections which lead to several malignancies in immunocompromised patients. Murine \u03b3HV 68 (MHV-68), a homolog to human EBV and KSHV, has been employed as a classical pathogen to investigate the molecular pathogenicity of \u03b3HV infections. \u03b3HV express distinct antigens during lytic or latent infection and antigen-specific T cells have a significant role in controlling the acute and latent viral infection, although the quality of anti-viral T cell responses required for protective immunity is not well-understood. We have generated recombinant modified vaccinia virus Ankara (recMVA) vaccines via MVA-BAC homologous recombination technology expressing MHV-68 ORF6 and ORF61 antigens encoding both MHC class I and II-restricted epitopes. After vaccination, we examined T cell responses before and after MHV-68 infection to determine their involvement in latent virus control. We show recognition of recMVA- and MHV-68-infected APC by ORF6 and ORF61 epitope-specific T cell lines in vitro. The recMVA vaccines efficiently induced MHV-68-specific CD8+ and CD4+ T cell responses after a single immunization and more pronounced after homologous prime/boost vaccination in mice. Moreover, we exhibit protective capacity of prophylactic recMVA vaccination during early latency at day 17 after intranasal challenge with MHV-68, but failed to protect from latency at day 45. Further T cell analysis indicated that T cell exhaustion was not responsible for the lack of protection by recMVA vaccination in long-term latency at day 45. The data support further efforts aiming at improved vaccine development against \u03b3HV infections with special focus on targeting protective CD4+ T cell responses.", "doi": "10.3389/fimmu.2019.02984", "pmid": "31921215", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC6930802"}], "notes": [], "created": "2026-08-21T12:58:49.405Z", "modified": "2026-08-21T12:58:49.432Z"}